Cargando…
Comparison of in vitro and in vivo Toxicity of Bupivacaine in Musculoskeletal Applications
The recent societal debate on opioid use in treating postoperative pain has sparked the development of long-acting, opioid-free analgesic alternatives, often using the amino-amide local anesthetic bupivacaine as active pharmaceutical ingredient. A potential application is musculoskeletal surgeries,...
Autores principales: | Steverink, Jasper G., Piluso, Susanna, Malda, Jos, Verlaan, Jorrit-Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915669/ https://www.ncbi.nlm.nih.gov/pubmed/35295435 http://dx.doi.org/10.3389/fpain.2021.723883 |
Ejemplares similares
-
Lack of concentration-dependent local toxicity of highly concentrated (5%) versus conventional 0.5% bupivacaine following musculoskeletal surgery in a rat model
por: Steverink, Jasper G., et al.
Publicado: (2023) -
Toxic Myelitis and Arachnoiditis After Intrathecal Delivery of Bupivacaine via an Implanted Drug Delivery System: Case Report and Review of the Literature
por: Huang, Meng, et al.
Publicado: (2018) -
Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain
por: Rahman, Md Shafiqur, et al.
Publicado: (2021) -
Effect of research participation versus usual clinical care in patients with rheumatic and musculoskeletal disorders: a prospective cohort study
por: Ginnerup-Nielsen, Elisabeth, et al.
Publicado: (2023) -
Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAmMOTH Study)
por: Macfarlane, Gary J, et al.
Publicado: (2021)